CytomX Therapeutics To Present Preclinical Data For Conditionally Activated Interferon Alpha-2b At The SITC 2023 Annual Meeting

CytomX Therapeutics, Inc. +2.76%

CytomX Therapeutics, Inc.




- IND filing for CX-801 anticipated by the end of 2023 -

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced that preclinical data supporting CX-801, its conditionally activated cytokine program, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California.


Details for the poster presentation are as follows:

Presentation Title: Conditionally activated IFNa induces an inflammatory tumor microenvironment in preclinical models and increases efficacy in combination with checkpoint blockade

Abstract Number: 1064

Poster Hall A

Session Date and Time: November 4, 2023, 9:00 am - 8:30 pm PT

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via